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ABSTRACT
After coronary stent implantation, neointima formation resembles the wound healing process 
as it involves the sequential processes of inflammation, granulation, and remodeling. Because 
antiproliferative drugs and polymers of drug-eluting stents (DESs) delay vascular healing 
compared with bare metal stents, fibrin deposition can remain long after stent implantation, 
or inflammation can be excessive. Delayed vascular healing can be associated with adverse 
clinical outcomes including DES thrombosis or restenosis, and poor endothelization of DES 
neointima can accelerate neoatherosclerotic change inside the neointima, further contributing 
to luminal restenosis or neointimal instability. Despite the lack of correlation between 
pathologic and optical coherence tomography (OCT) findings, OCT assessments of neointima 
under various circumstances can reveal vascular responses to stent therapy. Homogeneous, 
heterogeneous, and layered neointima patterns can be recognized by OCT and can change 
with time. Homogeneous neointima might be associated with better clinical outcomes after 
DES implantation, whereas non-homogeneous neointima or neoatherosclerotic change can 
be associated with poorer clinical outcomes. However, limited data are currently available, and 
further studies are required to comprehensively address these questions.
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INTRODUCTION
Pathologic and intravascular ultrasound studies have revealed the mechanisms of coronary 
stent failure. Despite treatment with drug-eluting stents (DESs), neointimal hyperplasia is 
considered to be an important mechanism of stent therapy failure.1) Therefore, additional 
information about neointimal hyperplasia is required to develop novel devices and improve 
stent therapy. Recently, optical coherence tomography (OCT) has been used to assess the 
morphologies of implanted coronary stents in detail in various clinical situations. With 
higher resolution than intravascular ultrasound, OCT can evaluate strut-level coverage 
and assess neointima more accurately.2) Accordingly, insights from OCT studies regarding 
neointimal hyperplasia can be helpful to physicians, researchers, and developers.
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The objective of this review is to describe the formation and transformation of neointima 
after DES implantation based on pathologic and OCT studies.
DELAYED VASCULAR HEALING OF DES
The earliest response after bare metal stent (BMS) implantation is deposition of platelets and 
fibrin around stent struts within 24 to 48 hours.3) Acute inflammatory cells such as neutrophils 
are concomitantly observed within platelet and fibrin aggregates. After the inflammatory 
phase, organization of the thrombus starts with migration and proliferation of smooth muscle 
cells in the granulation phase.4) Neointima containing smooth muscle cells can be recognized 
beginning about 14 days after stenting.3) At earlier times, synthetic smooth muscle cells appear 
and gradually re-differentiate into contractile α-actin-positive smooth muscle cells.4) In later 
phases, the smooth muscle cells rearrange along the lumen. The layer underneath the lumen 
is rich in smooth muscle cells and proteoglycans and tends to be compact with little matrix, 
while the area around stent struts tends to be less cellular and rich in proteoglycans.4) As tissue 
remodeling progresses, deposition of type I collagen increases with corresponding decreases in 
cellularity and extracellular matrix.4) Endothelization reaches 30% of the neointimal surface at 1 
month and 80% to 100% at 3 to 4 months in BMS.5)
Compared to BMSs, DESs contain antiproliferative drugs that inhibit the migration and 
proliferation of smooth muscle cells. From a registry of 40 autopsies, Cypher® (Cordis Corp., 
Miami Lakes, FL, USA) and Taxus® (Boston Scientific Corp., Marlborough, MA, USA) DESs 
showed a greater delay in healing, characterized by persistent fibrin deposition and poorer 
endothelization, than BMSs.5) The persistence of fibrin and incomplete endothelization 
far beyond 30 days from the time of stenting result in the critical pathologic substrate 
underlying late stent thrombosis.5) Currently available second-generation cobalt-chromium 
everolimus-eluting stents demonstrated greater strut coverage with less inflammation, 
less fibrin deposition, and less late and very late stent thromboses than first-generation 
Cypher® and Taxus® DESs.6) Although second-generation DESs share certain properties with 
first-generation DESs, the second-generation DESs have thin stent struts and are made of 
biocompatible polymers that are thromboresistent, which results in less flow disturbance, 
greater endothelial cell coverage, and less thrombus formation.6-8) Nevertheless, endothelial 
maturation appears later in everolimus-eluting stents compared with BMSs.6)9)
CORRELATIONS BETWEEN HISTOPATHOLOGIC 
FINDINGS AND OCT ASSESSMENTS OF NEOINTIMA
Gonzalo et al.10) described OCT patterns of stent restenosis. Homogeneous neointima has 
uniform optical properties and does not show focal variations in backscattering pattern. 
Heterogeneous neointima has focally changing optical properties and shows various 
backscattering patterns. Layered neointima consists of concentric layers with different 
optical properties: an adluminal high scattering layer and an abluminal low scattering layer 
(Figure 1).10) Normal neointima, defined as smooth muscle cell-rich tissue with extracellular 
matrix containing collagens and proteoglycans, is seen as homogeneous and has a smooth 
luminal surface. The peak intensity of optical frequency domain imaging is in the moderate 
range, and the attenuation rate is mild to moderate. However, areas of fibrin deposition 
or inflammation (hypersensitivity) that appear during the development of neointima 
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normally have a dark appearance.11) According to a histopathological validation study, a 
homogeneous pattern correlates most often with smooth muscle cells and a collagenous/
proteoglycan matrix, while a heterogeneous pattern is frequently associated with stent-
induced hypersensitivity vasculitis. A layered pattern is most commonly correlated to healed 
neointimal rupture/erosion. However, OCT pattern does not indicate a specific histologic 
finding even though OCT can visualize neointima in detail. Table 1 summarizes OCT patterns 
and corresponding histologic findings.12)
OBSERVATION OF DEVELOPMENT OF DES NEOINTIMA 
USING OCT
Because pathologic evaluations are not always possible in various clinical situations, 
assessment of neointima using OCT could provide additional information despite a lack of 
histologic validation. In addition, possible OCT findings related to neointimal development 
can be made based on the optical properties of neointimal components. During the 
inflammatory phase, depositions or aggregates of platelets and fibrin appear as dark areas 
on OCT. As the migration and proliferation of smooth muscle cells progress, bright areas 
underneath the lumen can increase. In the case of DESs, deposition of platelets/fibrin or 
inflammation (hypersensitivity) can be persistent over time, resulting in a heterogeneous 
OCT pattern. As smooth muscle cells proliferate, the neointimal pattern can become 
more homogeneous. If there is a large number of platelet/fibrin aggregates or elevated 
inflammation, the proliferation of smooth muscle cells beneath the lumen can cause the 
neointima to have a layered appearance on OCT. Notably, given the formation process of 
neointima, it is important to note that the neointimal pattern assessed by OCT might not 
be constant and should be interpreted across the neointimal formation continuum. Also 
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Figure 1. Homogeneous (A), heterogeneous (B), and layered patterns (C) observed by OCT. 
OCT = optical coherence tomography.
Table 1. OCT patterns and corresponding histologic findings
OCT patterns Histologic findings
Homogeneous neointima Smooth muscle cells and extracellular matrix
Organized thrombus
Heterogeneous neointima Hypersensitivity vasculitis related to stent
Smooth muscle cells in rich extracellular matrix
Layered neointima Healed neointimal rupture/erosion
Peristrut neovascularization
Smooth muscle cells in rich extracellular matrix
Neointimal calcification
OCT = optical coherence tomography.
of significance is that neointimal patterns classified by OCT examination can have various 
pathologies and are thus not conclusive.
From an observational OCT study investigating 507 DES-treated lesions with a mean 
neointimal thickness >100 μm, homogeneous neointima was the most common finding 3 to 
6 months after the index procedure.13) The frequency of heterogeneous neointima decreased 
gradually with time, and layered neointima was most frequently observed in restenotic 
DES lesions within 30 months after stenting.13) Figure 2 presents morphological changes in 
neointimal pattern during the follow-up period.14)
CLINICAL IMPLICATIONS OF OCT-DEFINED NEOINTIMAL 
PATTERNS
Non-homogeneous neointima patterns, including heterogeneous and layered patterns, were 
more commonly detected among restenotic DES lesions than a homogeneous neointima 
pattern. Non-homogeneous neointima accounted for about two-thirds of restenotic lesions, 
suggesting that early DES in-stent restenosis might be associated with delayed arterial 
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Figure 2. Serial changes in neointimal patterns after DES implantation as assessed by OCT. A 58-year-old female 
patient treated with Nobori® DES underwent serial OCT evaluations between 9 months and 2 years after stenting. 
At the 9-month follow-up, heterogeneous neointima was diffusely identified through the longitudinal axis (A, 
B, C). At the 2-year follow-up, heterogeneous neointima was partly changed into homogeneous (D) or layered 
pattern (E). In contrast, heterogeneous neointima was persistent in another segment (F). 
DES = drug-eluting stent; OCT = optical coherence tomography.
healing.15) A speckled pattern similar to that of heterogeneous neointima decreased with 
time, consistent with previous observations.13)15) According to a serial OCT study, there was a 
decrease in the area of homogeneous neointima at the second follow-up 9 to 18 months after 
DES implantation, whereas the amount of non-homogeneous neointima (heterogeneous 
plus layered patterns) did not change significantly.16) Given that neointimal regression was 
observed 6 months after BMS implantation,17) homogeneous neointima identified in DES 
might represent the natural healing process. In a clinical follow-up study of 336 patients 
with 368 DES-treated lesions, major adverse cardiac events, defined as the composite of 
cardiac death, nonfatal myocardial infarction, or target lesion revascularization, occurred 
less frequently in patients with homogeneous neointima during a median follow-up of 
31 months. Patients with heterogeneous neointima underwent major adverse cardiac 
events most frequently, suggesting the possibility that heterogeneous neointima might 
predict a poor clinical outcome.18) In drug-coated balloon angioplasty for DES restenosis, 
post-interventional luminal enlargement was similar between homogeneous and non-
homogeneous lesions. However, in homogeneous lesions, the luminal gain was driven 
primarily by an increase in stent area, whereas in non-homogeneous lesions, it more often 
resulted from a decrease in neointimal area.19) These findings suggest that mechanical 
resistance to balloon dilation can differ among neointimal patterns as assessed by OCT.20) 
Figure 3 shows neointimal changes before and after drug-coated balloon angioplasty in 
patients with DES restenosis.
ATHEROSCLEROTIC CHANGE INSIDE NEOINTIMA
Although the pathogenesis of neoatherosclerosis remains unknown, it is speculated that 
incomplete or immature endothelization allows a greater amount of lipoproteins to enter 
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Figure 3. Serial changes in neointima before (left panel) and after (right panel) drug-coated balloon angioplasty 
in in-stent restenotic lesions. (A) Homogeneous neointima: acute luminal gain was mostly derived from stent 
overexpansion (68.0%, 1.7 mm2/2.5 mm2). (B) Heterogeneous neointima: acute luminal gain was mostly derived 
from neointimal compression (85.0%, 1.7 mm2/2.0 mm2).
the neointima, leading to neoatherosclerosis.21) Accordingly, this process can be accelerated 
in the context of the greater delay in vascular healing associated with DESs than BMSs.22) It 
is also plausible that neoatherosclerosis following stent implantation seems to occur more 
rapidly than atherosclerosis in native coronary arteries.21) Assessment of neoatherosclerosis 
using OCT is challenging because accumulations of lipids have the same appearance as fibrin 
deposition or excessive inflammation.11) In addition, optical attenuation by red thrombi or 
macrophage accumulations, artifacts such as shadowing caused by blood inside of catheters, 
or tangential signal dropout can falsely identify lipidic neointima.23) However, as shown 
in Figure 4, a non-homogeneous pattern with an invisible stent strut on OCT imaging can 
identify the presence of lipids within neointima.24)
Clinical implications of neoatherosclerosis are consistent across pathologic and OCT studies; 
neoatherosclerosis contributes to late failure of stent therapy. The prevalence of very late 
stent thrombosis from neoatherosclerosis increases with time in both BMSs and first-
generation DESs.21)25-27) Neoatherosclerosis causes one-third of very late stent thrombosis 
cases.25-27) Notably, the timing of very late stent thrombosis from in-stent plaque rupture 
is substantially earlier in first-generation DESs than BMSs.22) Neoatherosclerosis has also 
been identified in both BMS and DES restenoses.21) Neoatherosclerosis generally increases 
the neointimal burden and contributes to development of in-stent restenosis.21) Among 
152 lesions with >50% neointimal stenosis, neoatherosclerosis was found in one-third.28) 
Patients with neoatherosclerosis (vs. those without neoatherosclerosis) had higher rates of 
target lesion revascularization and stent thrombosis.28) In a serial OCT study, the frequency 
of neointima with neoatherosclerosis increased between 9 months and 2 years, with a 
simultaneous increase in mean neointimal thickness.29) Accordingly, the late contribution 
of neoatherosclerosis to neointimal growth can possibly explain a late renarrowing phase 
of a triphasic luminal response that was found in a previous angiographic study.30) Figure 5 
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Figure 4. Various neoatherosclerotic neointima observed by OCT. (A) Neointima with lipid (arrow). (B) Neointima 
with calcification (arrow). (C) Lipidic neointima with disruption (arrow). (D) Ruptured neointima with thrombi (arrow). 
OCT = optical coherence tomography.
shows neoatherosclerotic changes of the neointima during the follow-up period. Clinical 
factors such as hypertension, current smoking, chronic kidney disease, and low-density 
lipoprotein cholesterol >70 mg/dL increased the risk of neoatherosclerosis, while the use 
of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockade reduced the 
risk of neoatherosclerosis.31)32) Although limited data are currently available, the frequency of 
neoatherosclerosis was comparable between first- and second-generation DESs according 
to both pathologic and OCT studies.6-33) This finding suggests that an innate antiproliferative 
property of DESs might play an important role in the development of neoatherosclerosis. 
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Figure 5. Development of in-stent neoatherosclerosis that caused DES restenosis. A 77-year-old male patient 
with exertional chest pain showed restenosis (arrow) of Cypher® DES in the left anterior descending artery (A). 
OCT evaluation showed lipidic neointima at the site of minimal luminal area (A). Three years prior, this patient 
underwent OCT evaluation that demonstrated relatively homogeneous neointima without significant luminal 
narrowing (B). The patient was successfully treated with Xience® DES implantation. 
DES = drug-eluting stent; OCT = optical coherence tomography.
Neoatherosclerosis was also observed in patients who had in-scaffold restenosis after 
successful treatment with bioresorbable vascular scaffold.34)35) To date, observed predictors 
for neoatherosclerosis, with the exception of DESs and older stent age, are not consistent 
across studies, and optimal prevention and treatment strategies for patients with 
neoatherosclerosis remain unknown.
CONCLUSION
Despite lack of histopathologic validation, OCT can be used to assess the presence of 
delayed vascular healing after DES implantation, keeping in mind the formation process 
of neointima. Homogeneous neointima can be related to better clinical outcomes, while 
non-homogeneous neointima or neoatherosclerotic change within the neointima can be 
associated with unfavorable clinical outcomes, such as restenosis and stent thrombosis.
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